Dynavax Technologies reported $167.74M in Sales Revenues for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US USD 14.81B 229M
Adma Biologics ADMA:US USD 41.09M 7.18M
Agenus AGEN:US USD 22.77M 1.85M
Amgen AMGN:US USD 6.65B 58M
AstraZeneca AZN:LN USD 10.98B 211M
Astrazeneca AZN:US USD 10.98B 211M
Biogen BIIB:US USD 2.51B 80.6M
Biomarin Pharmaceutical BMRN:US USD 505.34M 28.45M
Bristol Myers Squibb BMY:US USD 11.22B 669M
Chimerix CMRX:US USD 32.56M 32.12M
Dynavax Technologies DVAX:US USD 167.74M 88.73M
Gilead Sciences GILD:US USD 7.04B 782M
Glaxosmithkline GSK:US GBP 7.83B 900M
Merk MRK:US USD 14.96B 366M
Nektar Therapeutics NKTR:US USD 23.62M 2.04M
Neurocrine Biosciences NBIX:US USD 387.9M 9.7M
Novartis NOVN:VX USD 12.84B 243M
Pfizer PFE:US USD 22.64B 5.1B
Regeneron Pharmaceuticals REGN:US USD 2.94B 79M
Roche Holding ROG:VX CHF 32.3B 207M
Sarepta Therapeutics SRPT:US USD 230.27M 3.22M
Tg Therapeutics TGTX:US USD 94K 500K
Vertex Pharmaceuticals VRTX:US USD 2.33B 138.1M